ClinicalTrials.gg
RecruitingNCT06004739A-DONUTUpdated Sep 19, 2024

Antibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection

An interventional study of Start Antibiotics / Continue Antibiotics for treatment of bacteriuria and No Antibiotics for treatment of bacteriuria in Infectious Disease, sponsored by Mount Sinai Hospital, Canada. Recruiting at 7 sites in 2 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Mount Sinai Hospital, Canada · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Communicable Diseases with a site in Canada — 7 open to participants now, 8 under way, 2 of them phase 3. Communicable Diseases · Canada.

Planned enrollment
9th of 26
550 · median 125
Started
2024
with 1 other
No phase
12 of 34
2 open now
Registered
28th of 34
by date
Lead sponsor
3 of 34
Mount Sinai Hospital, Canada

Among the 34 studies in Communicable Diseases with a site in Canada, this one is the 9th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2024, is one of 12 with no phase, and was the 28th registered.

Communicable Diseases

628 studies on the registry are indexed under Communicable Diseases; 129 are open to participants now.

Browse Communicable Diseases studies →

Open to participants now

7 of the 34 studies in Communicable Diseases with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Communicable Diseases with a site in Canada, or all of them as a file.
02

Study summary

Delirium is an acute confusional state that is experienced by many older adults who are admitted to hospital. To treat delirium the underlying cause needs to be identified promptly, but this is challenging. One of the potential causes of delirium is infection. Urine tests show that most patients experiencing delirium have bacteria in their urine, however, bacteria in the urine is common among older adults, and does not automatically indicate an infection is present. As a result it is difficult to know whether a lower urinary tract infection is present as individuals with delirium are frequently unable to report clinical signs of infection - symptoms of pain or discomfort with urination, having to urinate more frequently or pelvic discomfort. Very often, individuals with delirium are treated with antibiotics despite the fact that it is unknown whether antibiotics help to improve delirium in cases where bacteria in the urine is present. This proposed study is a randomized controlled trial that will examine if adults (age 60 or older) with delirium and suspected infection benefit from taking antibiotics.

03

Conditions studied

  • Infectious Disease

Keywords

  • Delirium
  • Antibiotics
  • Older adults
  • Urinary Tract Infection
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 60 and admitted to a hospital ward (including rehabilitation hospital);
  • Active delirium (defined by CAM: [1] inattention AND [2] acute and fluctuating level of consciousness, and either [3] disorganized thinking OR [4] altered mental status; OR physician's diagnosis)
  • Less than 24 hours of antibiotics (prior to trial assessment)
  • Either pyuria (defined as white blood cells detected on urinalysis or dipstick) or bacteriuria (defined as bacteria growing on urine culture)

Exclusion criteria

Exclusion criteria

  • Fever (temperature > 37.9C or > 100.2F) in the past 48 hours;
  • Signs of lower urinary tract infection symptoms (such as new dysuria) or upper urinary symptoms (such as costovertebral tenderness)
  • In the opinion of the treating physician, there is a reason apart from delirium and urine test results to treat with antibiotics (e.g., pneumonia)
  • Indwelling urinary catheter for > 72 hours
  • Receipt of an antibiotic where a single dose suffices for the treatment of a UTI (such as Fosfomycin)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
550 participants (estimated)

Study arms

  • Other
    Antibiotics

    Participants will be randomized to start or continue with antibiotics. Antibiotic type and duration targeted to lower urinary tract infection as directed by the Most Responsible Physician (MRP).

    Drug: Start Antibiotics / Continue Antibiotics for treatment of bacteriuria

  • Other
    No Antibiotics

    Participants will be randomized to no antibiotics

    Other: No Antibiotics for treatment of bacteriuria

Interventions

  • DrugStart Antibiotics / Continue Antibiotics for treatment of bacteriuria

    Participants will be randomized to start or continue with antibiotics (with antibiotic duration determined by the Most Responsible Physician \[MRP\]). Antibiotics choice to be selected by the MRP.

  • OtherNo Antibiotics for treatment of bacteriuria

    Participants will be randomized to no antibiotics

06

What researchers measure

Primary outcomes

  1. Delirium at day 7 or at day of hospital discharge, whichever is earliest

    Delirium will be assessed using Confusion Assessment Method (CAM). CAM assesses 4 delirium features: \[1\] inattention, \[2\] acute and fluctuating level of consciousness, \[3\] disorganized thinking and \[4\] altered mental status. For a diagnosis of delirium by CAM, the patient must display feature \[1\] AND \[2\], AND EITHER \[3\] or \[4\].

    Time frame: Delirium will be assessed at the first of day 7 or discharge

Secondary outcomes

  1. Length of hospitalization

    Time frame: Up to 30 days

  2. Number of participants with bacteremia (bacteria isolated in blood culture)

    Time frame: Up to 7 days

  3. Number of participants who were transferred to Intensive Care Unit (ICU)

    Time frame: Up to 7 days

  4. Number of participants who had a fall

    Time frame: Up to 7 days

  5. Number of participants who were physically restrained

    Time frame: Up to 7 days

  6. Number of participants who received antipsychotics

    Time frame: Up to 7 days

  7. Days of antibiotics

    Time frame: Up to 7 days

  8. Number of participants with C. difficile infection

    C. difficile will be defined as a combination of a positive microbiological test for C. difficile (if still hospitalized at the time of diagnosis), or self-reported diagnosis of C. difficile (provided the patient reported diarrhea and receipt of an antibiotic to treat C. difficile)

    Time frame: By 30 days

  9. Number of participants who died

    Time frame: By 30 days

  10. Number of participants who died

    Time frame: By 365 days

  11. Number of participants who were readmitted to hospital

    Time frame: By 365 days

  12. Number of participants who were readmitted to hospital

    Time frame: By 30 days

07

Study locations

2 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Sep 2027, 40 months after the start.

Of 128 non-industry interventional studies with no phase under Communicable Diseases, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 36. This study's planned 40 months is above that.

Counting every sponsor, half of 144 studies reached it within 21 months; a quarter within 6 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2023
First posted
Aug 22, 2023
StartActual
May 18, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06004739
Collaborators
Sault Area Hospital, Michael Garron Hospital, Unity Health Toronto, The Ottawa Hospital, Northwestern Memorial Hospital
Responsible party
Sponsor
First posted
Aug 22, 2023
Start date
May 18, 2024
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Sep 19, 2024

Study contacts

Michael Fralick, MD
Contact
mike.fralick@mail.utoronto.ca
(416) 586-4800
Michael Fralick, MD, PhD
principal investigator · Sinai Health System
Chris Kandel, MD, PhD
principal investigator · Michael Garron Hospital
Nathan Stall, MD, PhD
principal investigator · Sinai Health System

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion